156 related articles for article (PubMed ID: 12177096)
1. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
[TBL] [Abstract][Full Text] [Related]
4. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
[TBL] [Abstract][Full Text] [Related]
7. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
9. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
[TBL] [Abstract][Full Text] [Related]
11. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
12. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
15. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
18. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
Small EJ; Meyer M; Marshall ME; Reyno LM; Meyers FJ; Natale RB; Lenehan PF; Chen L; Slichenmyer WJ; Eisenberger M
J Clin Oncol; 2000 Apr; 18(7):1440-50. PubMed ID: 10735891
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
20. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]